Kolltan Pharmaceuticals will in-license a monoclonal antibody from MedImmune, the global biologics R&D arm of AstraZeneca. The MAb targets the Her3 receptor tyrosine kinase. Based on the current program status, Kolltan anticipates initiating Phase I clinical testing of this product in 1Q14. Financial details of the agreement were not disclose, but both companies will have the potential for future cost-, risk- and profit-sharing for this product candidate after Kolltan completes early clinic...